Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.79 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.79 |
| ▸ | ERBB4 | Q15303 | 7/20 | 0.79 |
| ▸ | JAK3 | P52333 | 2/20 | 0.79 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.77 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 0.77 |
| ▸ | GAK | O14976 | 1/20 | 0.76 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.76 |
| ▸ | LCK | P06239 | 1/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.76 |
| ▸ | SRC | P12931 | 1/20 | 0.76 |
| ▸ | DRD2 | P14416 | 1/20 | 0.76 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.76 |
| ▸ | MC3R | P41968 | 1/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL869099 | 1.00 | EGFR (0.79) | EGFRERBB2ERBB4JAK3ERBB3 | |
| SCHEMBL29731545 | 1.00 | EGFR (0.79) | EGFRERBB2ERBB4JAK3ERBB3 | |
| SCHEMBL17498544 | 0.94 | EGFR (0.71) | EGFRERBB2ERBB4JAK3ERBB3 | |
| SCHEMBL16398699 | 0.93 | EGFR (0.79) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL16398696 | 0.93 | EGFR (0.79) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL25829 | 0.92 | EGFR (0.80) | EGFRERBB2ERBB4JAK3ERBB3 | |
| SCHEMBL18862642 | 0.92 | EGFR (0.80) | EGFRERBB2ERBB4JAK3ERBB3 | |
| SCHEMBL16405547 | 0.92 | EGFR (0.83) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL17498519 | 0.92 | EGFR (0.83) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL18427450 | 0.92 | EGFR (0.79) | EGFRERBB2ERBB4JAK3ERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564638-B2 | EGFR protein degradant and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2026-03-03 | — | — | US | disclosed |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-11-21 | — | — | US | disclosed |
| CN-117304170-A | Bifunctional molecule capable of degrading EGFR mutant and preparation method and application thereof | 中国药科大学 | 2023-12-29 | — | — | CN | disclosed |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-10-06 | — | — | US | disclosed |
| CN-112321566-B | EGFR protein degradation agent and anti-tumor application thereof | 上海科技大学 | 2022-06-10 | — | — | CN | disclosed |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| WO-2021023233-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | 上海科技大学 | 2021-02-11 | — | — | WO | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20150065709-A1 | Aminoquinazoline Derivative And Use Thereof In Preparing Anti-Malignant Tumor Medicament | METABOMICS, INC. (CN) | 2015-03-05 | — | — | US | disclosed |
| WO-2015007219-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015007219-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2015-01-22 | — | — | WO | disclosed |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2014-06-12 | — | — | US | disclosed |
| WO-2012159457-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 山东亨利医药科技有限责任公司 (CN) | 2012-11-29 | — | — | WO | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065709-A1 | Aminoquinazoline Derivative And Use Thereof In Preparing Anti-Malignant Tumor Medicament | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885ERBB4 3/4885 |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | EGFR 2/4885ERBB2 6/4885ERBB4 11/4885 |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885ERBB4 4/4885 |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | EGFR 48/4885ERBB2 7/4885ERBB4 17/4885 |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885ERBB4 4/4885 |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | EGFR 2/4885ERBB2 6/4885ERBB4 11/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | EGFR 41/4885ERBB2 7/4885ERBB4 15/4885 |
| US-12564638-B2 | EGFR protein degradant and anti-tumor application thereof | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885ERBB4 6/4885 |
| US-20140161801-A1 | QUINAZOLINE DERIVATIVE AS TYROSINE-KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JAK1, JAK2, YES1 | EGFR 194/4885ERBB2 53/4885ERBB4 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.